CD274 and neoplasm: Several blocking antibodies against PD-1/PD-L1 have been approved for clinical use in humans (6), and preclinical studies have demonstrated that combining PD-1/PD-L1 axis blockade with CAR-T cells or systemically administered T-bsAb can improve anti-tumor activity (62–64).